Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

BMS Nabs Global Rights to Ambrx' Fibroblast Growth Factor and Relaxin Candidates for $24M

Preclinical programs for the treatment of type 2 diabetes and heart failure are based on Ambrx’ amino acid-based protein modification platform.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »